Opthea Ltd. | Mutual Funds
Mutual Funds that own Opthea Ltd.
Fidelity Funds SICAV - Asian Smaller Companies Fund
1,749,160
0.86%
-51,545
0.1%
05/31/2018
UniSector: BioPharma
1,000,000
0.49%
-4,000,000
0.13%
03/31/2018
Fidelity Asian Values Plc
819,456
0.4%
0
0.1%
05/31/2018
Nestor Australien Fonds
575,778
0.28%
0
1.76%
06/29/2018
Fidelity Japan Japan/Asia Growth Equity Mother Fund
327,577
0.16%
-14,548
0.28%
12/11/2017
Fidelity Funds SICAV - International Fund
32,664
0.02%
637
0%
03/31/2018
Fidelity Funds SICAV - Multi Asset Strategic Fund
14,385
0.01%
51
0%
03/31/2018
Fidelity Funds SICAV - Multi Asset Strategic Defensive Fund
6,899
0%
-77
0%
03/31/2018
Fidelity Funds SICAV - Target 2040 (EUR) Fund
1,065
0%
62
0%
03/31/2018
Fidelity Funds SICAV - Target 2030 (EUR) Fund
969
0%
56
0%
03/31/2018
| Address |
650 Chapel Street
South Yarra Victoria (VIC) 3141
Australia
|
|
Employees
|
- |
| Website |
http://www.opthea.com |
| Updated |
07/08/2019 |
| Opthea Ltd. is engaged in developing biological therapeutics for cancer and other serious diseases. It is a biologics drug developer building on its significant intellectual property portfolio around Vascular Endothelial Growth Factor C and D angiogenic molecules and R3. The company focuses on vascular endothelial growth factors to develop truly novel therapies to extend and improve the lives of cancer sufferers. |
